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Abstract
Summary Findings from this 5-year phase 3 study of
postmenopausal women with osteoporosis showed that
bazedoxifene was associated with an overall favorable
safety and tolerability profile, with no evidence of
endometrial or breast stimulation. Overall, the results at
5 years were consistent with those seen at 3 years.
Introduction We report safety and tolerability findings from
a 5-year randomized, double-blind, phase 3 study of
bazedoxifene in postmenopausal women with osteoporosis.
Methods In the core study, healthy postmenopausal women
with osteoporosis (N=7,492; mean age, 66.4 years) were
randomized to daily doses of bazedoxifene 20 or 40 mg,
raloxifene 60 mg, or placebo for 3 years. During the 2-year
study extension, the raloxifene 60-mg treatment arm was
discontinued after the 3-year database was finalized, and
subjects receiving bazedoxifene 40 mg were transitioned in a
blinded manner to bazedoxifene 20 mg (bazedoxifene 40-/
20-mg group) after 4 years. Safety and tolerability data are
reported for subjects in the bazedoxifene 20- and 40-/20-mg
and placebo groups; efficacy findings are reported elsewhere.
Results A total of 3,146 subjects in the bazedoxifene 20-
and 40-mg and placebo groups were enrolled in the
extension study (years 4 and 5). Overall, the 5-year
incidence of adverse events (AEs), serious AEs, and
discontinuations due to AEs were similar among groups.
The incidence of hot flushes and leg cramps was higher
with bazedoxifene compared with placebo. Venous throm-
boembolic events, primarily deep vein thrombosis, were
more frequently reported in the bazedoxifene groups
compared with the placebo group. Reports of cardiac
disorders and cerebrovascular events were few and evenly
distributed among groups. Bazedoxifene showed a neutral
effect on the breast and endometrium.
Conclusion Bazedoxifene was associated with an overall
favorable safety and tolerability profile in postmenopausal
women with osteoporosis over 5 years of therapy, consis-
tent with findings at 3 years.
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Introduction
Osteoporosis, a skeletal disease of diminished bone strength
and increased fracture risk, is characterized by decreased
bone mineral density (BMD) and microarchitectural dete-
rioration [1, 2]. Postmenopausal women are at increased
risk for fracture as the production of ovarian estrogens
ceases after menopause [3]. Osteoporotic fractures are
associated with substantial morbidity and mortality and
can have a significant impact on health care costs and the
patient’s quality of life [4, 5]. Numerous agents for the
prevention and/or treatment of postmenopausal osteoporo-
sis are currently available, including bisphosphonates,
estrogen therapy, parathyroid hormone (PTH), calcitonin,
strontium ranelate (outside the USA and Canada), and the
selective estrogen receptor modulator (SERM) raloxifene
[1]. Although existing pharmacologic agents for postmen-
opausal osteoporosis have been shown to be effective [6],
they may not be appropriate for all women, primarily
because of safety or tolerability concerns [7].
A number of novel SERMs are under clinical investiga-
tion for the prevention and/or treatment of postmenopausal
osteoporosis [8]. SERMs confer mixed estrogen receptor
(ER) agonist or antagonist activity depending on the target
tissue [9]. There are several “class effects” that are
commonly observed with SERMs, including an increased
incidence of hot flushes [8, 10–12] and venous thrombo-
embolic events (VTEs) [13–15]. Raloxifene has also been
associated with an increased risk of fatality due to stroke,
although the overall risk of stroke has not been shown to be
significantly different compared with placebo [13].
Bazedoxifene is a novel SERM in late-stage develop-
ment for the prevention and treatment of postmenopausal
osteoporosis. In a 2-year, phase 3 study [16, 17] of
postmenopausal women at risk for osteoporosis (N=
1,583), bazedoxifene 10, 20, and 40 mg were shown to
prevent bone loss and to reduce bone turnover, with a
favorable endometrial, ovarian, and breast safety profile. In
a 3-year pivotal, global phase 3 study [18] of postmeno-
pausal women with osteoporosis (N=7,492), bazedoxifene
20 and 40 mg were shown to significantly reduce the risk of
new vertebral fracture relative to placebo; in a subgroup of
higher-risk women (n=1,772), bazedoxifene 20 mg signif-
icantly decreased the risk of nonvertebral fracture compared
with both placebo and raloxifene 60 mg. Both doses of
bazedoxifene were generally safe and well tolerated and
showed no evidence of endometrial or breast stimulation
[18, 19]. Many of the subjects completing the 3-year core
study chose to participate in a 2-year extension study, in
which extended treatment with bazedoxifene showed
sustained efficacy in preventing fractures over 5 years of
therapy [20]. Herein, we describe the results of safety-
related endpoints from the extension study; we hypothe-
sized that, consistent with findings at 3 years, bazedoxifene
would be associated with a favorable safety and tolerability
profile over 5 years of therapy.
Methods
Study design and subjects
The core study was a 3-year multicenter, randomized,
double-blind, placebo- and active-controlled phase 3 trial
[18] conducted at 206 sites worldwide and was followed by
two 2-year extensions (second 2-year extension is ongoing).
Subjects were randomly assigned to receive once-daily oral
doses of bazedoxifene 20 or 40 mg, raloxifene 60 mg, or
placebo for 3 years. All subjects received oral daily
elemental calcium (up to 1,200 mg) and vitamin D (400–
800 IU) supplementation. Subjects who were enrolled in
the 3-year core study were generally healthy postmeno-
pausal women aged 55 to 85 years with osteoporosis,
defined as low BMD or radiographically confirmed
vertebral fractures. Subjects without prevalent vertebral
fracture were required to have lumbar spine or femoral neck
BMD T-scores between −2.5 and −4.0 (inclusive), whereas
subjects with a prevalent vertebral fracture (at least one
mild vertebral fracture) were required to have lumbar spine
or femoral neck BMD T-scores not worse than −4.0.
A complete description of the inclusion and exclusion
criteria for the core study has been published previously
[18]. Exclusion criteria included diseases that may affect
bone metabolism or conditions that could interfere with
measurement of BMD, pathologic vertebral fractures,
vasomotor symptoms requiring treatment, active or past
history of VTEs, endometrial hyperplasia or carcinoma,
abnormal vaginal bleeding, or malignancy within 10 years
of the study. Subjects were prohibited from the use of
androgens, systemic estrogens (except estriol ≤2.0 mg/day),
topical estrogens (>3 times/week), progestogens, SERMs,
bisphosphonates, calcitonin, PTH, and cholecalciferol
(>50,000 IU/week) within 6 months of screening.
During the extension study, investigators were instructed
to prescribe a bisphosphonate or calcitonin (in cases of poor
tolerance to bisphosphonates) to subjects experiencing a
7% or greater decrease from baseline in BMD at the lumbar
spine or hip or at least one osteoporosis-related fracture
(confirmed by a dual X-ray absorptiometry scan or X-ray,
respectively) based on the protocol.
Subjects in the raloxifene 60-mg treatment arm were
discontinued after all subjects completed 3 years of
treatment and the database for the 3-year core study was
finalized. Those subjects receiving bazedoxifene 40 mg
were transitioned to bazedoxifene 20 mg (bazedoxifene 40-/
20-mg group) after all subjects completed 4 years of
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treatment. All treatment groups remained blinded through-
out the study. The safety data reported herein are for the
bazedoxifene 20-mg, bazedoxifene 40/20-mg, and placebo
groups. The study protocol (including any amendments)
and an informed consent form were submitted to the
independent ethics committee or institutional review board
at each institution for review and written approval. All
subjects who were willing to participate in the study
extension provided written informed consent at or prior to
their visit at month 36. The study was conducted in
accordance with the ethical principles outlined in the
Declaration of Helsinki.
Assessments
Safety and tolerability were assessed based on physical
examinations, gynecologic and breast examinations, mam-
mography, cervical cytology smears, clinical laboratory
determinations, and adverse event (AE) reporting. During
the extension, physical and gynecologic examinations,
laboratory safety determinations, and mammography were
performed at months 48 and 60 or upon withdrawal from
the study (if >9 months had elapsed since the last
assessment). In nonhysterectomized women, cervical cytol-
ogy smear was done at month 48 or upon withdrawal if
more than 18 months had elapsed since the last assessment
during the study extension. As previously described [19],
transvaginal ultrasound (TVU) of the uterus and ovaries
and endometrial biopsy was performed for those subjects
participating in the endometrial safety substudy at month 60
(or upon withdrawal from the study if at or after month 48).
The US Food and Drug Administration’s Coding Symbols
for Thesaurus of Adverse Reaction Terms were used to
classify AEs.
Independent adjudication boards were formed to ensure
a consistent, accurate, and unbiased assessment of the
following AEs of interest: VTEs, cerebrovascular events
(stroke or transient ischemic attack [TIA]), and breast
cancer. The adjudication boards were composed of consul-
tant physicians specializing in the fields of internal
medicine with expertise in VTEs, cardiology, breast cancer,
neurology, and neuroradiology. All adjudication board
members reviewed each case independently in a blinded
manner. Thereafter, a final decision was determined for
each case based on majority or consensus decision,
according to the guidance set forth in each of the
adjudication board charters.
Statistical analyses
Safety data were analyzed in all subjects who received at
least one dose of study medication during the 5-year study.
Differences in the incidence of AEs, serious AEs, and
discontinuations due to AEs among treatment groups were
evaluated using chi-square analysis, with a significance
level set at 0.05. The incidence of VTEs and cerebrovas-
cular events based on adjudicated data were expressed as
the rate in 1,000 women-years. Hazard ratios (HRs) of
treatment versus placebo were calculated using a propor-
tional hazard model without adjustment for possible
covariates; corresponding 95% confidence intervals (CIs)
were obtained.
Results
Subjects
A total of 7,492 women received ≥1 dose of study
medication and were included in the safety population over
the 5-year study. Of the 5,083 subjects who completed the
3-year core study, 3,146 subjects in the bazedoxifene 20-
and 40-mg and placebo groups were enrolled in a 2-year
extension study (Fig. 1). All subjects in the raloxifene 60-
mg group who enrolled in the extension (n=1,070) were
discontinued after the database for the 3-year core study
was finalized, and subjects receiving bazedoxifene 40 mg
were transitioned to bazedoxifene 20 mg (bazedoxifene 40-/
20-mg group; n=1,041) after 4 years. Baseline character-
istics and demographics of subjects who were enrolled in
the extension study were not different among treatment
groups (Table 1) and were generally similar to those who
were originally enrolled in the core study [18]. At the time
of enrollment into the core study, the mean age of subjects
who continued on to the extension study was 65.9 years,
the mean time since last menstrual period was 18.8 years,
and the vast majority of women (91.9%) had natural
menopause. A total of 2,503 subjects completed years 4
and 5 of the extension study (Fig. 1); there were no
significant differences in the percentage of subjects who
discontinued from the study among treatment groups. The
most common reason for discontinuation was patient
request, followed by AEs.
Over 5 years of therapy, the incidences of AEs, serious
AEs, and discontinuations due to AEs in the bazedoxifene
treatment groups were not different from that seen in the
placebo group (Table 2). Fifty-five subjects in the bazedox-
ifene and placebo groups had deaths that were reported to
the sponsor during the 5-year study: bazedoxifene 20 mg,
n=24 (1.3%); bazedoxifene 40/20 mg, n=18 (1.0%);
placebo, n=13 (0.7%). Although the overall number of
deaths during the 5-year study period was greater in the
bazedoxifene groups compared with the placebo group, the
differences were not statistically significant and were not
attributable to any group of related causes. Cause of death
was classified into one of four categories: cardiovascular,
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oncology, other (which included infection, trauma, upper
gastrointestinal bleed, chronic obstructive pulmonary
disease, subdural hematoma, myeloproliferative disease,
aspiration, postoperative complication, and suicide), and
unknown. The numeric imbalance in deaths was due to a
greater number of deaths in the categories of oncology and
other: for subjects in the bazedoxifene 20- and 40-/20-mg
and placebo groups, respectively, there were seven, five,
and six deaths in the cardiovascular group; nine, four, and
five deaths in the oncology group; six, five, and one death
in the “other” group; and two, four, and one death in the
“unknown” group. For the oncology-related deaths, there
was no specific organ system affected.
The most frequently reported AEs were back pain,
arthralgia, pain, flu syndrome, infection, accidental injury,
abdominal pain, headache, and hypertension (Table 2).
Among AEs reported by >10% of subjects in any treatment
group, the incidences of leg cramps and hot flushes were
higher in the bazedoxifene treatment groups compared with
the placebo group (overall P<0.01 and P<0.001, respec-
tively). Most reports of leg cramps and hot flushes were
mild or moderate in severity and did not result in study
discontinuation.
Cardiac disorders
The number of subjects reporting cardiac disorders was
low and similar among groups over the 5-year study
period. There were no significant differences among the
bazedoxifene and placebo groups in the number of
subjects reporting coronary occlusion (bazedoxifene
20 mg [n=2], bazedoxifene 40/20 mg [n=1], placebo
[n=2]), myocardial infarction (bazedoxifene 20 mg [n=9],
bazedoxifene 40/20 mg [n=10], placebo [n=11]), and
myocardial ischemia (bazedoxifene 20 mg [n=12], baze-
doxifene 40/20 mg [n=13], placebo [n=12]).
Cerebrovascular events
The incidence of cerebrovascular events based on adjudicated
data was similar overall among the bazedoxifene and placebo
groups over 5 years and was similar to that seen over the first
3 years (Table 3). The rates of total stroke per 1,000 women-
years were 2.5 with bazedoxifene 20 mg, 2.7 with bazedox-
ifene 40/20 mg, and 3.0 with placebo (corresponding HRs
[95% CI] of 0.8 [0.4–1.6] and 0.9 [0.5–1.8], respectively;
Table 3) over 5 years. There were no significant differences
Fig. 1 Subject disposition. The number of subjects who were
enrolled, completed, and discontinued the 3-year core study and the
2-year study extension are shown, with reasons for discontinuation
provided. The raloxifene treatment arm was discontinued in the fourth
year, and subjects receiving bazedoxifene 40 mg were transitioned to
bazedoxifene 20 mg after 4 years
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in the rates of stroke (total, hemorrhagic, ischemic, or
unspecified) among treatment groups. Reports of TIA were
most frequent in the bazedoxifene 40-/20-mg group (HR
[95% CI] of 3.1 [0.99–9.52]; Table 3); the difference relative
to placebo was not statistically significant. All cases of TIA
were reported in subjects who received bazedoxifene 40 mg
before they were transitioned to bazedoxifene 20 mg. There
were a total of five fatal strokes over 5 years: bazedoxifene
20 mg (n=2), bazedoxifene 40/20 mg (n=1), and placebo
(n=2).
VTEs
A total of 41 VTEs were reported during the 5-year study.
The incidence of VTEs (0.7%) based on adjudicated data
was higher among subjects treated with bazedoxifene
versus placebo over 5 years (Table 4); the differences were
not statistically significant. The rates of any VTE per
1,000 women-years were 2.3 with bazedoxifene 20 mg, 2.6
with bazedoxifene 40/20 mg, and 1.6 with placebo
(corresponding HRs [95% CI] of 1.5 [0.7–3.4] and 1.7
[0.8–3.6], respectively; Table 4) after 5 years. For clinical
perspective, the rate of any VTE per 1,000 women-years for
raloxifene 60 mg based on available data was 2.3 (95% CI
[1.2–3.9]). The incidence of deep vein thrombosis (DVT)
was higher in the bazedoxifene treatment groups compared
with the placebo group; the rates per 1,000 women-years
were 1.4 with bazedoxifene 20 mg, 1.8 with bazedoxifene
40/20 mg, and 0.5 with placebo (corresponding HRs [95%
CI] of 3.0 [0.8–11.1] and 3.8 [1.1–13.5], respectively).
Similarly, the rates of superficial thrombophlebitis were
higher in the bazedoxifene treatment groups compared with
the placebo group. There were no differences in the rates of
pulmonary embolism (PE) and retinal vein thrombosis
(RVT) among the bazedoxifene and placebo groups.
Breast and reproductive safety
The number of subjects with breast carcinoma was small
and evenly distributed among the bazedoxifene 20-mg (n=
10), bazedoxifene 40-/20-mg (n=9), and placebo groups
(n=10; Table 5). Of these, invasive breast carcinoma was
diagnosed in nine subjects in the bazedoxifene 20-mg
group, seven subjects in the bazedoxifene 40-/20-mg group,
and seven subjects in the placebo group. This included one
subject in the bazedoxifene 20-mg group who had a
baseline lesion subsequently diagnosed as breast cancer
during the study. In addition, there was no significant
difference among groups in the number of subjects who had
ER-positive breast cancer (bazedoxifene 20 mg [n=4],
Table 1 Baseline characteristics and demographics for subjects enrolled in the extension study (years 4 and 5)a
Characteristic Bazedoxifene 20 mg (n=1,047) Bazedoxifene 40/20 mg (n=1,041) Placebo (n=1,058)
Age, years
Mean (SD) 65.9 (6.3) 65.7 (6.4) 65.9 (6.5)
Ethnic origin, n (%)
White 924 (88.3) 893 (85.8) 921 (87.1)
Black 70 (6.7) 91 (8.7) 72 (6.8)
Hispanic 42 (4.0) 41 (3.9) 43 (4.1)
Otherb 11 (1.1) 16 (1.5) 22 (2.1)
Years since last menstrual period
Mean (SD) 19.0 (8.2) 18.7 (8.4) 18.7 (8.5)
Hysterectomy, n (%) 204 (19.5) 214 (20.6) 191 (18.1)
Type of menopause, n (%)
Natural 965 (92.2) 948 (91.1) 977 (92.3)
Surgical oophorectomy 82 (7.8) 93 (8.9) 81 (7.7)
Hot flushes, n (%) 148 (14.1) 158 (15.2) 136 (12.8)
BMI, kg/m2
Mean (SD) 26.5 (3.7) 26.3 (3.9) 26.3 (3.8)
Lumbar spine BMD T-score
Mean (SD) −2.4 (1.09) −2.5 (1.08) −2.4 (1.08)
Patients with prevalent vertebral fracture, % 54 53 55
SD standard deviation, BMI body mass index, BMD bone mineral density
a Data were collected at baseline of the 3-year core study
b Includes Asian, Native American, and other ethnic origins
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bazedoxifene 40/20 mg [n=3], placebo [n=5]). The
incidence of breast cyst or fibrocystic breast disease was
not significantly different among treatment groups, al-
though there were fewer cases with bazedoxifene 20 and
40/20 mg compared with placebo. The incidence of breast
pain was not significantly different among the bazedoxifene
and placebo groups.
The incidence of endometrial hyperplasia and neopla-
sia (polyps) over 5 years was low and evenly distributed
among groups. Fewer cases of endometrial carcinoma
(overall P=0.05) were reported with bazedoxifene 20 mg
(n=0) and bazedoxifene 40/20 mg (n=3) compared with
placebo (n=6). TVU data were available for 176 subjects
at baseline and at year 5 (bazedoxifene 20 mg, n=60;
bazedoxifene 40/20 mg, n=58; placebo, n=58). The
mean change (± standard error) from baseline in
endometrial thickness with bazedoxifene 20 mg (−0.04
±0.13 mm) and bazedoxifene 40/20 mg (0.07±0.13 mm)
was not significantly different from that seen with
placebo (−0.19±0.13 mm) at 5 years. The number of
subjects with endometrial thickness >5 mm at 5 years
was small and similar among the bazedoxifene 20-mg
(n=0), bazedoxifene 40-/20-mg (n=2), and placebo (n=
0) groups.
Table 2 Summary of safety profile over 5 years
Subjects, n (%) Bazedoxifene 20 mg (n=1,886) Bazedoxifene 40/20 mg (n=1,872) Placebo (n=1,885)
Any AE 1,821 (96.6) 1,807 (96.5) 1,826 (96.9)
Any serious AE 467 (24.8) 439 (23.5) 439 (23.3)
Discontinuations due to
AE 317 (16.8) 325 (17.4) 293 (15.5)
Deaths 24 (1.3) 18 (1.0) 13 (0.7)
AEs >10% in any treatment group
Back pain 666 (35.3) 640 (34.2) 659 (35.0)
Arthralgia 653 (34.6) 638 (34.1) 643 (34.1)
Pain 620 (32.9) 604 (32.3) 647 (34.3)
Flu syndrome 526 (27.9) 511 (27.3) 547 (29.0)
Infection 514 (27.3) 493 (26.3) 504 (26.7)
Accidental injury* 504 (26.7) 443 (23.7) 527 (28.0)
Abdominal pain 450 (23.9) 449 (24.0) 496 (26.3)
Headache 463 (24.5) 465 (24.8) 463 (24.6)
Hypertension 460 (24.4) 451 (24.1) 452 (24.0)
Constipation 376 (19.9) 367 (19.6) 350 (18.6)
Cough 238 (12.6) 220 (11.8) 225 (11.9)
Leg cramps* 256 (13.6) 249 (13.3) 192 (10.2)
Asthenia 230 (12.2) 220 (11.8) 223 (11.8)
Hot flushes** 245 (13.0) 251 (13.4) 124 (6.6)
Peripheral edema 226 (12.0) 205 (11.0) 185 (9.8)
Diarrhea 189 (10.0) 229 (12.2) 210 (11.1)
Dizziness 223 (11.8) 190 (10.1) 212 (11.2)
Urinary tract infection 219 (11.6) 203 (10.8) 199 (10.6)
Dyspepsia 206 (10.9) 191 (10.2) 216 (11.5)
Bronchitis 200 (10.6) 213 (11.4) 187 (9.9)
Hypercholesteremia** 196 (10.4) 152 (8.1) 224 (11.9)
Arthrosis 185 (9.8) 194 (10.4) 191 (10.1)
Insomnia 190 (10.1) 172 (9.2) 199 (10.6)
Pharyngitis 166 (8.8) 179 (9.6) 205 (10.9)
Select AEs
Cataract, specified 112 (5.9) 108 (5.8) 113 (6.0)
Cataract, nonspecified 0 1 (0.1) 1 (0.1)
AE adverse event
*P<0.01 (chi-square test); **P<0.001 (chi-square test)
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There were four histopathologically confirmed cases of
ovarian carcinoma: bazedoxifene 20 mg (n=3), bazedoxifene
40/20 mg (n=1), and placebo (n=0). For two additional
subjects in the bazedoxifene 20-mg group, ovarian
carcinoma was reported as an AE. Subsequent review of
these histopathology reports showed a primary papillary
peritoneal serous adenocarcinoma for one subject; for the
other subject, the primary diagnosis was unknown. The
incidence of uterine or vaginal bleeding was similar among
the bazedoxifene and placebo groups.
Discussion
Overall, bazedoxifene was associated with a favorable
safety and tolerability profile with no evidence of endome-
trial or breast stimulation over 5 years of therapy in
postmenopausal women with osteoporosis; the findings at
5 years were consistent with those seen at 3 years [18]. The
incidence of AEs, serious AEs, and discontinuations due to
AEs in the bazedoxifene groups was similar to that observed
in the placebo group. Also consistent with findings at
3 years and previous studies of SERMs [8, 10–12, 18, 21],
there was a higher incidence of hot flushes and leg cramps
with bazedoxifene compared with placebo at 5 years,
although most of these events were mild or moderate in
severity and did not lead to study discontinuation.
Treatment with bazedoxifene was associated with a
higher risk of VTE compared with placebo, which was
primarily due to an increased incidence of DVTs; the risk of
PE or RVT was similar among the bazedoxifene and
placebo groups. The majority of VTEs occurred early on,
during the first 2 years of the study. Treatment with
raloxifene has been associated with the highest relative risk
(RR) of VTE during year 1 (RR, 6.0; 95% CI, 1.4–25.5)
and year 2 (RR, 6.6; 95% CI, 0.9–50.4) [14], which
decreased to 3.1 (95% CI, 0.9–10.4) during years 4 to
8 [15]. Overall, the increased risk of VTEs seen with
bazedoxifene relative to placebo (HR, 1.5–1.7) over 5 years
is similar to that in longer-term evaluations of raloxifene
(HR, 1.4–2.1) [13, 14] and lasofoxifene (HR, 2.1–2.7) [22].
Also consistent with the 3-year findings [18], the risk of
cardiac disorders (coronary occlusion, myocardial infarc-
tion, and myocardial ischemia) and stroke (ischemic,
hemorrhagic, or unspecified) with bazedoxifene was similar
and not significantly different from that with placebo at
5 years. Raloxifene has been associated with a small but
significant increase in the incidence of fatal stroke
compared with placebo over 5.6 years of follow-up (RR,
1.49; 95% CI, 1.00–2.24; P=0.05), although there has been
Table 3 Rate and hazard ratio of cerebrovascular events over 5 yearsa
Bazedoxifene 20 mg (n=1,886) Bazedoxifene 40/20 mg (n=1,872) Placebo (n=1,885)
Stroke (total)
n (%) 16 (0.8) 17 (0.9) 19 (1.0)
Rate per 1,000 women-years (95% CI) 2.5 (1.4–4.1) 2.7 (1.6–4.3) 3.0 (1.8–4.6)
HR (95% CI) 0.8 (0.43–1.63) 0.9 (0.48–1.77)
Hemorrhagic
n (%) 1 (0.1) 1 (0.1) 4 (0.2)
Rate per 1,000 women-years (95% CI) 0.2 (0.0–0.9) 0.2 (0.0–0.9) 0.6 (0.2–1.6)
HR (95% CI) 0.3 (0.03–2.24) 0.3 (0.03–2.28)
Ischemic
n (%) 12 (0.6) 14 (0.7) 13 (0.7)
Rate per 1,000 women-years (95% CI) 1.9 (1.0–3.3) 2.2 (1.2–3.8) 2.0 (1.1–3.5)
HR (95% CI) 0.9 (0.42-2.02) 1.1 (0.52-2.35)
Unspecified
n (%) 3 (0.2) 2 (0.1) 2 (0.1)
Rate per 1,000 women-years (95% CI) 0.5 (0.1–1.4) 0.3 (0.0–1.2) 0.3 (0.0–1.1)
HR (95% CI) 1.5 (0.25–8.96) 1.0 (0.15–7.31)
TIA
n (%) 6 (0.3) 12 (0.6) 4 (0.2)
Rate per 1,000 women-years (95% CI) 0.9 (0.3–2.0) 1.9 (1.0–3.3) 0.6 (0.2–1.6)
HR (95% CI) 1.5 (0.42–5.33) 3.1 (0.99–9.52)
CI confidence interval, HR hazard ratio, TIA transient ischemic attack
a Based on review by an independent adjudication board
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no evidence of a difference in the overall risk of stroke [13].
In the current study, the number of cardiovascular-related
deaths (including stroke) was similar among the bazedox-
ifene and placebo groups. There was an increased number
of TIAs observed in the bazedoxifene 40-/20-mg group
compared with the other groups; this difference was not
statistically significant. The similar incidence of ischemic
strokes with both bazedoxifene doses relative to placebo
does not support a causative relationship between bazedox-
ifene 40 mg and TIA.
Table 5 Incidence of breast- and reproductive system–related adverse events
Subjects, n (%) Bazedoxifene 20 mg (n=1,886) Bazedoxifene 40/20 mg (n=1,872) Placebo (n=1,885)
Breast carcinoma 10 (0.5)a 9 (0.5) 10 (0.5)
Breast cyst 11 (0.6) 11 (0.6) 16 (0.8)
Fibrocystic breast disease 7 (0.4) 10 (0.5) 14 (0.7)
Breast neoplasm 16 (0.8) 18 (1.0) 22 (1.2)
Breast pain 57 (3.0) 50 (2.7) 51 (2.7)
Endometrial carcinoma* 0 3 (0.2) 6 (0.3)
Endometrial hyperplasia 1 (0.1) 1 (0.1) 1 (0.1)
Endometrial neoplasia (polyps) 13 (0.7) 16 (0.9) 14 (0.7)
Ovarian carcinoma 3 (0.2)b 1 (0.1) 0
Ovarian cyst 21 (1.1) 11 (0.6) 16 (0.8)
Uterine hemorrhage 4 (0.2) 6 (0.3) 5 (0.3)
Vaginal hemorrhage 19 (1.0) 22 (1.2) 28 (1.5)
*P=0.05 (chi-square test)
a Includes one case with breast lesion at baseline and diagnosed later on in the study
b Excludes 2 cases that were not confirmed as ovarian carcinoma by histopathology
Table 4 Rate and hazard ratio of venous thromboembolic events and superficial thrombophlebitis over 5 yearsa
Bazedoxifene 20 mg (n=1,886) Bazedoxifene 40/20 mg (n=1,872) Placebo (n=1,885)
Any VTE
n (%) 15 (0.8) 16 (0.9) 10 (0.5)
Rate per 1,000 women-years (95% CI) 2.3 (1.3–3.9) 2.6 (1.5–4.1) 1.6 (0.8–2.9)
HR (95% CI) 1.5 (0.68–3.35) 1.7 (0.75–3.63)
DVT
n (%) 9 (0.5) 11 (0.6) 3 (0.2)
Rate per 1,000 women-years (95% CI) 1.4 (0.6–2.7) 1.8 (0.9–3.1) 0.5 (0.1–1.4)
HR (95% CI) 3.0 (0.81–11.09) 3.8 (1.05–13.51)
PE
n (%) 4 (0.2) 3 (0.2) 4 (0.2)
Rate per 1,000 women-years (95% CI) 0.6 (0.2–1.6) 0.5 (0.1–1.4) 0.6 (0.2–1.6)
HR (95% CI) 1.0 (0.25–4.01) 0.8 (0.17–3.47)
RVT
n (%) 2 (0.1) 2 (0.1) 3 (0.2)
Rate per 1,000 women-years (95% CI) 0.3 (0.0–1.1) 0.3 (0.0–1.2) 0.5 (0.1–1.4)
HR (95% CI) 0.7 (0.11–4.00) 0.7 (0.11–4.10)
Superficial thrombophlebitis
n (%) 13 (0.7) 21 (1.1) 10 (0.5)
Rate per 1,000 women-years (95% CI) 2.0 (1.1–3.5) 3.4 (2.1–5.1) 1.6 (0.8–2.9)
HR (95% CI) 1.3 (0.57–2.97) 2.2 (1.01–4.57)
VTE venous thromboembolic event, CI confidence interval, HR hazard ratio, DVT deep vein thrombosis, PE pulmonary embolism, RVT retinal
vein thrombosis
a Based on review by an independent adjudication board
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Endometrial safety is an important concern with the use
of SERMs due to their association with uterine stimulation.
For instance, several other SERMs (e.g., idoxifene, levor-
meloxifene) that were under clinical evaluation for post-
menopausal osteoporosis were discontinued because they
were associated with adverse endometrial effects [11, 23–
26].
Bazedoxifene was associated with a favorable endome-
trial and breast safety profile over 5 years of therapy,
consistent with previous clinical investigations [16, 17, 19,
27]. There was no change in endometrial thickness in the
bazedoxifene groups compared with the placebo group at
5 years. The incidence of breast- and reproductive system–
related AEs with bazedoxifene was similar to that with
placebo. There were fewer cases of endometrial carcinoma
in the bazedoxifene groups compared with the placebo
group. The number of subjects with breast cancer and
fibrocystic breast disease was small and not significantly
different among the bazedoxifene and placebo groups.
A reduced risk of breast cancer has been reported with
tamoxifen and raloxifene [14, 28, 29]. Bazedoxifene was
not associated with a decrease in breast cancer risk at
5 years, consistent with our findings at 3 years [18].
Raloxifene was also not associated with a reduction in
breast cancer risk at 3 years [18], in contrast to previous
reports [13, 30, 31]; this may be attributed to the relatively
small number of subjects evaluated and the overall low
baseline risk for breast cancer as assessed by the Gail index
(5-year risk <1.6 for all groups).
Strengths of the study include the large sample size of
postmenopausal women with osteoporosis who were
followed for 5 years, enabling the collection of long-term
safety data. There were a few potential limitations. Because
only those subjects who completed the core study were
eligible for enrollment in the extension, it may be possible
that the extension study population was somewhat different
(e.g., overall healthier) compared with the core study
population. However, the baseline characteristics and
demographics of subjects who continued on in the study
extension were not different among groups and were
generally similar to those enrolled in the core study [18].
Also, interpretation of data for subjects in the bazedoxifene
40-/20-mg group may be a challenge if considerable
differences were observed between the two bazedoxifene
doses; however, both the efficacy and safety findings were
similar among the groups.
In conclusion, findings from this 2-year extension study
showed that bazedoxifene was generally safe and well
tolerated in postmenopausal women with osteoporosis, with
no evidence of endometrial or breast stimulation over
5 years of therapy. The findings at 5 years were consistent
with those seen at 3 years. Combined with the sustained
antifracture effect seen with bazedoxifene, these findings
support a favorable long-term benefit−risk profile of
bazedoxifene in the treatment of osteoporosis in postmen-
opausal women.
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